Fennec Pharmaceuticals Inc. (TSE:FRX - Get Free Report)'s share price passed above its fifty day moving average during trading on Wednesday . The stock has a fifty day moving average of C$8.86 and traded as high as C$9.46. Fennec Pharmaceuticals shares last traded at C$9.46, with a volume of 408 shares trading hands.
Analysts Set New Price Targets
Separately, Stephens upgraded Fennec Pharmaceuticals to a "strong-buy" rating in a research note on Monday, November 18th.
Check Out Our Latest Report on Fennec Pharmaceuticals
Fennec Pharmaceuticals Stock Performance
The company has a market capitalization of C$188.99 million, a P/E ratio of -166.01 and a beta of 0.25. The company has a debt-to-equity ratio of -620.83, a current ratio of 7.80 and a quick ratio of 10.17. The company has a fifty day moving average price of C$8.91 and a two-hundred day moving average price of C$7.72.
Insider Buying and Selling
In related news, Senior Officer Robert Christopher Andrade purchased 15,816 shares of Fennec Pharmaceuticals stock in a transaction on Monday, November 18th. The shares were purchased at an average price of C$3.43 per share, for a total transaction of C$54,248.88. Also, Director Rostislav Christov Raykov sold 10,000 shares of Fennec Pharmaceuticals stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of C$8.76, for a total value of C$87,552.00. In the last ninety days, insiders have acquired 41,612 shares of company stock worth $157,868 and have sold 13,617 shares worth $122,514. 16.20% of the stock is owned by corporate insiders.
About Fennec Pharmaceuticals
(
Get Free Report)
Fennec Pharmaceuticals Inc operates as a biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons.
Read More
Before you consider Fennec Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Fennec Pharmaceuticals wasn't on the list.
While Fennec Pharmaceuticals currently has a "Strong Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
